Viewing Study NCT02306694


Ignite Creation Date: 2025-12-25 @ 1:33 AM
Ignite Modification Date: 2026-02-11 @ 7:44 PM
Study NCT ID: NCT02306694
Status: COMPLETED
Last Update Posted: 2020-04-01
First Post: 2014-11-25
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Prospective Biomarkers of Bone Metabolism in Hemophilia A
Sponsor: Oregon Health and Science University
Organization:

Study Overview

Official Title: Prospective Biomarkers of Bone Metabolism in Hemophilia A
Status: COMPLETED
Status Verified Date: 2020-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: One of the major shortcomings in studying bone disease in hemophilia is the lack of fracture outcome data demonstrating the clinical significance of decreased BMD and altered bone biomarkers in the hemophilia population. This study demonstrates that PwH have an increased risk of fracture compared to the general population and that the issue of bone health will increase in importance as the PwH population ages.
Detailed Description: This is a pilot study to determine the impact of factor replacement on bone biomarkers in up to 20 hemophilia A subjects. Subjects will be recruited over 1 year for the 5-day protocol.

Following a 72-hour washout period, factor levels and bone biomarkers will be followed before and after 50 units/kg replacement on Day 1 and 20 units/kg replacement on Day 3. Each subject can serve as their Figure 4. Fracture rates in PwH compared to historic controls.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: